MLchartDataset catalogue

Tipifarnib

Term · Oncology and biomedicine · MLC-T-ONC-008717

  1. A substance that is being studied in the treatment of acute myeloid leukemia (AML) and other types of cancer. It belongs to the family of drugs called farnesyltransferase inhibitors. Also called R115777 and Zarnestra.

  2. A nonpeptidomimetic quinolinone with potential antineoplastic activity. Tipifarnib binds to and inhibits the enzyme farnesyl protein transferase, an enzyme involved in protein processing (farnesylation) for signal transduction. By inhibiting the farnesylation of proteins, this agent prevents the activation of Ras oncogenes, inhibits cell growth, induces apoptosis, and inhibits angiogenesis.

Table 1. Record
IdentifierMLC-T-ONC-008717
FieldOncology and biomedicine
SynonymsR115777; Zarnestra
ReferencesNCI Dictionary of Cancer Terms; National Cancer Institute Thesaurus (CC BY 4.0)
Record as JSON
{
  "id": "MLC-T-ONC-008717",
  "term": "Tipifarnib",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A substance that is being studied in the treatment of acute myeloid leukemia (AML) and other types of cancer. It belongs to the family of drugs called farnesyltransferase inhibitors. Also called R115777 and Zarnestra.",
    "A nonpeptidomimetic quinolinone with potential antineoplastic activity. Tipifarnib binds to and inhibits the enzyme farnesyl protein transferase, an enzyme involved in protein processing (farnesylation) for signal transduction. By inhibiting the farnesylation of proteins, this agent prevents the activation of Ras oncogenes, inhibits cell growth, induces apoptosis, and inhibits angiogenesis."
  ],
  "synonyms": [
    "R115777",
    "Zarnestra"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/tipifarnib/"
}

Record 16,385 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.